BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 22614882)

  • 21. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis.
    Koldingsnes W; Nossent JC
    J Rheumatol; 2003 Jan; 30(1):80-8. PubMed ID: 12508394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease.
    Fautrel B; Borget C; Rozenberg S; Meyer O; Le Loët X; Masson C; Koeger AC; Kahn MF; Bourgeois P
    J Rheumatol; 1999 Feb; 26(2):373-8. PubMed ID: 9972972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
    Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy.
    Pagnoux C; Quéméneur T; Ninet J; Diot E; Kyndt X; de Wazières B; Reny JL; Puéchal X; le Berruyer PY; Lidove O; Vanhille P; Godmer P; Fain O; Blockmans D; Bienvenu B; Rollot F; Aït el Ghaz-Poignant S; Mahr A; Cohen P; Mouthon L; Perrodeau E; Ravaud P; Guillevin L;
    Arthritis Rheumatol; 2015 Apr; 67(4):1117-27. PubMed ID: 25693055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
    Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
    Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.
    Reinhold-Keller E; Beuge N; Latza U; de Groot K; Rudert H; Nölle B; Heller M; Gross WL
    Arthritis Rheum; 2000 May; 43(5):1021-32. PubMed ID: 10817555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients.
    Ribi C; Cohen P; Pagnoux C; Mahr A; Arène JP; Puéchal X; Carli P; Kyndt X; Le Hello C; Letellier P; Cordier JF; Guillevin L;
    Arthritis Rheum; 2010 Apr; 62(4):1186-97. PubMed ID: 20131268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions.
    Morishita K; Guzman J; Chira P; Muscal E; Zeft A; Klein-Gitelman M; Uribe AG; Abramson L; Benseler SM; Eberhard A; Ede K; Hashkes PJ; Hersh AO; Higgins G; Imundo LF; Jung L; Kim S; Kingsbury DJ; Lawson EF; Lee T; Li SC; Lovell DJ; Mason T; McCurdy D; O'Neil KM; Punaro M; Ramsey SE; Reiff A; Rosenkranz M; Schikler KN; Scuccimarri R; Singer NG; Stevens AM; van Mater H; Wahezi DM; White AJ; Cabral DA;
    J Rheumatol; 2012 Oct; 39(10):2012-20. PubMed ID: 22859342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of ANCA-associated systemic vasculitis.
    Belmont HM
    Bull NYU Hosp Jt Dis; 2006; 64(1-2):60-6. PubMed ID: 17121492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate.
    Ozen S; Duzova A; Bakkaloglu A; Bilginer Y; Cil BE; Demircin M; Davin JC; Bakkaloğlu M
    J Pediatr; 2007 Jan; 150(1):72-6. PubMed ID: 17188618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Morishita KA; Moorthy LN; Lubieniecka JM; Twilt M; Yeung RSM; Toth MB; Shenoi S; Ristic G; Nielsen SM; Luqmani RA; Li SC; Lee T; Lawson EF; Kostik MM; Klein-Gitelman M; Huber AM; Hersh AO; Foell D; Elder ME; Eberhard BA; Dancey P; Charuvanij S; Benseler SM; Cabral DA;
    Arthritis Rheumatol; 2017 Jul; 69(7):1470-1479. PubMed ID: 28371513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.
    Hiemstra TF; Walsh M; Mahr A; Savage CO; de Groot K; Harper L; Hauser T; Neumann I; Tesar V; Wissing KM; Pagnoux C; Schmitt W; Jayne DR;
    JAMA; 2010 Dec; 304(21):2381-8. PubMed ID: 21060104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical features and outcomes of ANCA-associated renal vasculitis.
    Seck SM; Dussol B; Brunet P; Burtey S
    Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):301-5. PubMed ID: 22382223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.
    Mahr AD; Jover JA; Spiera RF; Hernández-García C; Fernández-Gutiérrez B; Lavalley MP; Merkel PA
    Arthritis Rheum; 2007 Aug; 56(8):2789-97. PubMed ID: 17665429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
    Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
    J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.
    Kuzuya K; Morita T; Kumanogoh A
    RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
    Pullerits R; Ljevak M; Vikgren J; Bokarewa M
    Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.